This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.
Transfusion medicine reviews · 2025
Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.
Acta haematologica · 2025
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Systematic reviews · 2023
Latest funding
- $2,000,000
Allogeneic regulatory T cell therapy to prevent graft versus host disease
CIHR · 2024 · Principal investigator
- $956,250
Targeting metabolic vulnerabilities in childhood cancers using immunotherapy
CIHR · 2023 · Co-investigator
- $20,000
Allogeneic regulatory T cell therapy to prevent chronic graft versus host disease
CIHR · 2023 · Principal investigator
8 publications.
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.
Lalu MM, Igweokpala S, Kekre N, Jeffers MS, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Giguere P, Sabri E, Sobh M, Fergusson DA
Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival.
Bai N, Limvorapitak W, Henderson R, Abou Mourad Y, Chung S, Forrest D, Hay K, Kuchenbauer F, Nantel S, Narayanan S, Nevill T, Power M, Rodrigo J, Roy C, Sanford D, Song K, Stubbins R, Sutherland H, Toze C, White J
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Lalu MM, Kekre N, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Sobh M, Fergusson DA
Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.
Khalife R, Montroy J, Grigor EJM, Fergusson DA, Atkins H, Seftel M, Presseau J, Thavorn K, Holt RA, Hay K, Lalu MM, Kekre N
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL, Stukas S, Cooper J, Thiara S, Chen LYC, Biggs CM, Hay K, Lee AYY, Shojania K, Abdulla A, Wellington CL, Sekhon MS
Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.
El-Galaly TC, Cheah CY, Kristensen D, Hutchison A, Hay K, Callréus T, Villa D
Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma.
Hay K, Lee B, Goktepe O, Connors JM, Sehn LH, Savage KJ, Klasa R, Shenkier T, Gerrie A, Villa D
Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia.
Lee B, Goktepe O, Hay K, Connors JM, Sehn LH, Savage KJ, Shenkier T, Klasa R, Gerrie A, Villa D
Allogeneic regulatory T cell therapy to prevent graft versus host disease
Principal investigators: Levings, Megan K; Schultz, Kirk R; Ahmad, Imran; Dijke, Ilona E; Hay, Kevin A; Lad, Deepesh P; West, Lori J
Keywords: Cell Therapy; Graft Versus Host Disease; Regulatory T Cells; Tolerance; Transplantation
Targeting metabolic vulnerabilities in childhood cancers using immunotherapy
Principal investigators: Sorensen, Poul H
Keywords: Cell Metabolism; Ewing Sarcoma; Il1rap; Immunotherapy; Metastasis
Allogeneic regulatory T cell therapy to prevent chronic graft versus host disease
Principal investigators: Levings, Megan K; Delisle, Jean-Sébastien; Ahmad, Imran; Dijke, Ilona E; Elsawy, Mahmoud E; Hay, Kevin A; Kekre, Natasha; Szwajcer, David; West, Lori J
Keywords: Cell Therapy; Graft Versus Host Disease; Regulatory T Cells; Tolerance; Transplantation
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
Development of second-generation radiopharmaceuticals targeting the C-X-C chemokine receptor 4 for imaging and therapy of hematological cancers
Principal investigators: Benard, Francois
Keywords: Cancer Therapy; Chemokine Receptors; Cxcr4; Lymphoma; Multiple Myeloma; Nuclear Medicine; Positron Emission Tomography; Radioisotopes; Radiopharmaceuticals
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
Allogeneic thymus-derived Tregs to prevent chronic inflammation in transplantation.
Principal investigators: Levings, Megan K; Dijke, Ilona E; West, Lori J
Keywords: Cell Therapy; Graft Versus Host Disease; Health Economics; Immune Tolerance; Organ Rejection; Regulatory T Cells; Transplantation
A Phase I first-in-human trial of CLIC-2201, a VHH-CD22 CAR-T cell product for the treatment of relapsed/refractory CD22 positive B-cell non-Hodgkin lymphoma
Principal investigators: Hay, Kevin A; Kekre, Natasha
Keywords: Adoptive Immunotherapy; Car-T Cells; Chimeric Antigen Receptor; Diffuse Large B-Cell Lymphoma (Dlbl); Non-Hodgkin'S Lymphoma; Phase I Clinical Trial
Lentiviral infusion as a universal approach for genetically modified immune effector cell therapies.
Principal investigators: Holt, Rob
Keywords: Cancer Immunotherapy; Car-T; Gene Expression; Gene Therapy; Gene Transfer Vectors; Immune Effector Cells; Lentivirus; Leukemia; Lymphoma; Synthetic Promoters
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- School of Epidemiology and Public Health
- Department of Medicine
- Surgery
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Natasha Kekre
Department of Medicine
3 shared papers, latest 2025
Harold Atkins
Department of Medicine
3 shared papers, latest 2025
Brian Hutton
School of Epidemiology and Public Health
2 shared papers, latest 2025
Justin Presseau
School of Epidemiology and Public Health
1 shared papers, latest 2020
Kednapa Thavorn
School of Epidemiology and Public Health
1 shared papers, latest 2020
Kednapa Thavorn
Faculty
1 shared papers, latest 2020
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.